OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Choueiri on the FDA Approval of Adjuvant Pembrolizumab in RCC

November 19th 2021

Toni K. Choueiri, MD, discusses the FDA approval of adjuvant pembrolizumab in renal cell carcinoma.

Dr. Moutafi on the Results of a Study Evaluating Biomarkers of Resistance in NSCLC

November 19th 2021

Myrto Moutafi, MD, MSc, discusses the results of a study evaluating biomarkers of resistance in non–small cell lung cancer.

Dr. Nebhan on the Efficacy of Checkpoint Inhibitors in Older Patients With Cancer

November 19th 2021

Caroline Nebhan, MD, PhD, discusses the efficacy of checkpoint inhibitors in older patients with cancer.

Dr. Mesa on Navigating the Expanding Paradigm of JAK Inhibitors in MPNs

November 19th 2021

Ruben A. Mesa, MD, discusses strategies for navigating the expanding paradigm of JAK inhibitors in myeloproliferative neoplasms.

Dr. Wildiers on the Final Results of the AIPAC Trial in HR+/HER2- Metastatic Breast Cancer

November 19th 2021

Hans Wildiers, MD, medical oncologist, Department of Medical Oncology, full professor, Faculty of Medicine, member, Laboratory of Experimental Oncology, University Hospital Leuven, Leuven, Belgium, discusses the final results of the phase 2b AIPAC trial (NCT02614833) in hormone receptor (HR)–positive, HER2-negative metastatic breast cancer.

Dr. Cheng on Advances With Immunotherapy-Based Combinations in Oncology

November 19th 2021

Jonathan D. Cheng, MD, discusses advances with immunotherapy-based combinations in oncology.

Dr. Stefanovic on the Emergence of Umbralisib in MZL and Follicular Lymphoma

November 18th 2021

Alexandra Stefanovic, MD, discusses the emergence of umbralisib in marginal zone lymphoma and follicular lymphoma.

Dr. Ramnaraign on Current Treatment Guidelines for First-Line Metastatic RCC

November 18th 2021

Brian Ramnaraign, MD, discusses current first-line treatment guidelines for patients with metastatic renal cell carcinoma.

Dr. El-Rayes on the Efficacy of Tidutamab in Advanced NETs

November 18th 2021

Bassel El-Rayes, MD, discusses the efficacy of tidutamab in advanced neuroendocrine tumors.

Dr. Kunz on the Importance of Tailoring Treatments to Patients With NETs

November 18th 2021

Pamela Kunz, MD, discusses the importance of tailoring treatments to individual patients with neuroendocrine tumors.

Dr. Toppmeyer on the Utility of De-Escalation Trials in HER2+ Breast Cancer

November 18th 2021

Deborah L. Toppmeyer, MD, discusses the utility of clinical trials evaluating de-escalated treatment approaches in HER2-positive breast cancer.

Dr. Ghodoussipour on Ongoing Trials in Non–Muscle Invasive Bladder Cancer

November 18th 2021

Saum Ghodoussipour, MD, discusses ongoing trials in non–muscle invasive bladder cancer.

Dr. Toomey on the Importance of De-Escalation Clinical Trials in HER2+ Breast Cancer

November 18th 2021

Kathleen C. Toomey, medical oncologist, discusses the importance of clinical trials evaluating de-escalated treatment strategies in HER2-positive breast cancer.

Dr. Shah on Trials Examining Cilta-Cel in Relapsed/Refractory Multiple Myeloma

November 18th 2021

Mansi R. Shah, MD, discusses ongoing research examining the CAR T-cell therapy ciltacabtagene autoleucel for the treatment of patients with relapsed or refractory multiple myeloma.

Dr. Cooper on Leveraging Novel Agents and Combos in Multiple Myeloma

November 18th 2021

Dennis Cooper, MD, sheds light on the novel therapeutic regimens available to patients with multiple myeloma.

Dr. Li on the Interim Results of a Phase 1 Trial With Surufatinib in NETs

November 17th 2021

Daneng Li, MD, discusses the interim analysis results of a phase 1 trial evaluating surufatinib in United States patients with neuroendocrine tumors.

Dr. Reidy-Lagunes on the Results of the SPINET Study by Tumor Subtype in BP-NETs

November 17th 2021

Diane Reidy-Lagunes, MD, discusses the results of the phase 3 SPINET trial by tumor subtype in bronchopulmonary neuroendocrine tumors.

Dr. Kimmick on the Evolving HER2+ Breast Cancer Treatment Paradigm

November 16th 2021

Gretchen G. Kimmick, MD, MS, discusses the quickly evolving treatment paradigm for patients with HER2-positive breast cancer.

Dr. Raj on Injection Site Pain With Octreotide Long-Acting Release Vs Lanreotide in NETs

November 16th 2021

Nitya Raj, MD, discusses the results of a phase 4 trial comparing injection site pain with octreotide long-acting release vs lanreotide in well-differentiated neuroendocrine tumors.

Dr. Halperin on the Efficacy of the Protocol PEN-221-001 Study in Advanced GI NETs

November 16th 2021

Daniel M. Halperin, MD, discusses the efficacy and safety results of the phase 1/2a Protocol PEN-221-001 trial in advanced gastrointestinal mid-gut neuroendocrine tumors.